H.C. Wainwright Sticks to Its Buy Rating for Rani Therapeutics Holdings (RANI)

Tip Ranks
2025.11.07 11:56
portai
I'm PortAI, I can summarize articles.

H.C. Wainwright analyst Brandon Folkes has maintained a Buy rating for Rani Therapeutics Holdings (RANI), setting a price target of $11.00. The consensus among analysts is a Strong Buy with an average price target of $10.00. Folkes has an average return of -1.2% and a success rate of 40.33%, covering the Healthcare sector.

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Rani Therapeutics Holdings, with a price target of $11.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Folkes is an analyst with an average return of -1.2% and a 40.33% success rate. Folkes covers the Healthcare sector, focusing on stocks such as MannKind, Achieve Life Sciences, and Eupraxia Pharmaceuticals.

Currently, the analyst consensus on Rani Therapeutics Holdings is a Strong Buy with an average price target of $10.00.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.